How the New OMB Rule Replaces Peer Review with Appointee Oversight for US R&D

On May 29, 2026, the White House Office of Management and Budget (OMB) published a 412-page proposed rule that fundamentally rewrites how the United States government distributes federal funding. Titled the "Regulation for Federal Financial Assistance," the proposal seeks to convert the existing Uniform Guidance—a flexible framework used by agencies to manage grants—into a strict, legally binding regulation.[1][3]

While the rule applies to all federal financial assistance, its most profound impact lands on the American scientific enterprise, which relies on over $110 billion in annual federal research and development (R&D) funding. The proposal systematically dismantles the post-World War II consensus that insulated scientific funding from political interference, replacing it with a system of direct executive oversight.[1]

For nearly 80 years, agencies like the National Institutes of Health (NIH) and the National Science Foundation (NSF) have relied on independent peer review. Under this system, panels of subject-matter experts evaluate grant applications based on scientific merit, methodology, and potential impact before any taxpayer money is awarded.

The new OMB rule explicitly strips peer review of its determinative power. The regulatory text states that peer review recommendations "remain advisory and are not ministerially ratified, routinely deferred to, or otherwise treated as de facto binding." This effectively demotes the scientific community's judgment to a mere suggestion in the final funding decision.[3]

In place of expert consensus, the rule mandates a "pre-issuance review" for all discretionary grants. Before any funds can be obligated, a senior political appointee within the agency must personally review and approve the award. These appointees are instructed to use their independent judgment to ensure that every funded project demonstrably advances the President's policy priorities and the broader national interest.[4]

The administration and its proponents argue that this overhaul is a necessary corrective for a system that lacks democratic accountability. By centralizing authority, the OMB aims to ensure that taxpayer dollars are not spent on projects the administration views as wasteful, out of scope, or ideologically driven. Proponents maintain that the elected government, rather than unelected academic panels, should have the final say over public expenditures.[3][4]

The scientific community has reacted with widespread alarm. Researchers and advocacy groups warn that subjecting grant approvals to political litmus tests will severely compromise the integrity of American science. Critics argue that evaluating proposals based on political alignment rather than scientific rigor risks funding substandard research while rejecting vital studies that conflict with an administration's ideology.[1][2]

The rule's mechanisms of control extend well beyond the initial award phase. It grants federal agencies expanded "termination for convenience" authority, allowing political appointees to cancel active, multi-year grants at any time if they determine the research no longer aligns with agency goals or the national interest.[4]

For research institutions and universities, this introduces unprecedented financial unpredictability. If a multi-year grant is abruptly terminated mid-project, universities could be left covering the costs of specialized laboratory equipment, long-term facilities, and the salaries of graduate students and research staff, making it highly risky to accept federal grants in the first place.

The proposal also imposes strict ideological and content-based boundaries on what can be researched. It explicitly prohibits the use of federal funds for diversity, equity, and inclusion (DEI) initiatives, "gender ideology," and disparate-impact studies—research that examines whether policies disproportionately harm specific demographic groups.[2]

Furthermore, the rule heavily restricts international scientific collaboration. Expanding on policies that previously applied only to specific agencies, the new regulation would ban federal funds from supporting partnerships with foreign entities unless there is explicit statutory authorization or a special waiver granted by a senior appointee.[1][4]

In a move that could reshape how scientific discoveries are shared, the rule also restricts the use of grant funds for publishing results or attending conferences. Researchers would generally be prohibited from using federal money to cover the costs of publishing in peer-reviewed journals, potentially forcing them to publish behind paywalls or seek alternative funding just to disseminate their findings to the public.[1]

The rulemaking process is operating on a highly compressed schedule. The OMB has provided a 45-day public comment period, which closes on July 13, 2026. Despite the sweeping nature of the 412-page document, the administration intends to finalize the rule quickly, targeting an effective date of October 1, 2026, to coincide with the start of the new federal fiscal year.[3][4]